Last reviewed · How we verify
TRC105 and Pazopanib
At a glance
| Generic name | TRC105 and Pazopanib |
|---|---|
| Also known as | Chimeric Antibody (TRC105) to CD105, Votrient |
| Sponsor | Tracon Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (PHASE1, PHASE2)
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRC105 and Pazopanib CI brief — competitive landscape report
- TRC105 and Pazopanib updates RSS · CI watch RSS
- Tracon Pharmaceuticals Inc. portfolio CI